14th week of 2019 patent applcation highlights part 20 |
Patent application number | Title | Published |
20190100730 | TREATING DIABETES WITH GENETICALLY MODIFIED BETA CELLS - Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12. | 2019-04-04 |
20190100731 | EX-VIVO INTESTINAL CULTURE MODEL, METHODS OF PRODUCING SAME AND USES THEREOF - A method of preparing an ex-vivo intestinal culture model is provided. The method comprising:
| 2019-04-04 |
20190100732 | ASSAY FOR THE REMOVAL OF METHYL-CYTOSINE RESIDUES FROM DNA - An isolated polynucleotide encoding a fusion protein which comprises a catalytically inactive CRISPR associated 9 (dCas9) protein linked to a TET protein is disclosed. Use thereof and of the fusion protein itself is also disclosed. | 2019-04-04 |
20190100733 | FACTORS FOR THE PRODUCTION AND ACCUMULATION OF POLYUNSATURATED FATTY ACIDS (PUFAS) DERIVED FROM PUFA SYNTHASES - Factors For the Production and Accumulation of Polyunsaturated Fatty Acids (PUFAs) Derived from PUFA Synthases Abstract Disclosed are novel enhancing factor proteins of the PUFA synthase systems, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified microorganisms comprising the same, and methods of making and using the same. Also disclosed are genetically modified microorganisms that have been genetically modified to express a PUFA synthase system for the production of PUFAs, wherein the microorganisms have been modified to express the novel enhancing factor proteins of the PUFA synthase system. | 2019-04-04 |
20190100734 | PHYTASE - Polypeptides having phytase activity and polynucleotide sequences encoding the phytases are provided. The gene expresses the phytase at a level of at least 7 g/l to 40 g/L. The phytases have higher specific activity, retain activity at low pH, retain activity at high temperature, increased phosphorous equivalency, increased phosphorous bioavailability, and increased phosphorous hydrolysis. The phytases can be used in a variety of industries including food, feed, ethanol production, pharmaceuticals, and cleaning. | 2019-04-04 |
20190100735 | Neurodegenerative disorders - A cyclic polypeptide, derivative or analogue thereof, comprising an amino acid sequence derived from the C-terminus of acetylcholinesterase (ACh E), or a truncation thereof. | 2019-04-04 |
20190100736 | METHOD FOR USING HEAT-RESISTANT MISMATCH ENDONUCLEASE - Provided are a mismatch-specific cleavage reaction using a novel heat-resistant mismatch nuclease, a method for removing errors in a nucleic acid amplification reaction using the mismatch nuclease, a method for inhibiting the amplification of a nucleic acid having a specific base sequence during a nucleic acid amplification reaction, and a method for detecting a nucleic acid having a single-base polymorphic mutation using this inhibition method. | 2019-04-04 |
20190100737 | PEPTIDE-MEDIATED DELIVERY OF RNA-GUIDED ENDONUCLEASE INTO CELLS - A composition is disclosed that comprises at least one protein component of an RNA-guided endonuclease (RGEN) and at least one cell-penetrating peptide (CPP), wherein the RGEN protein component and CPP are covalently or non-covalently linked to each other in an RGEN protein-CPP complex. The RGEN protein-CPP complex can traverse (i) a cell membrane, or (ii) a cell wall and cell membrane, of a cell. The RGEN protein component of an RGEN protein-CPP complex in certain embodiments can be associated with a suitable RNA component to provide an RGEN capable of specific DNA targeting. Further disclosed are compositions comprising at least one protein component of a guide polynucleotide/Cas endonuclease complex and at least one CPP, as well as methods of delivering RGEN proteins into microbial cells, as well as methods of targeting DNA with RGENs. | 2019-04-04 |
20190100738 | A Liquid Formulation of Alpha-Amylase - The present disclosure relates to liquid enzyme formulations containing one or more alpha-amylases for use in starch processing, wherein the pH of the enzyme formulation is about pH 6.0-8.0, and methods of use thereof. The present disclosure further relates to methods of making a liquid enzyme formulation containing one or more alpha-amylase having improved stability, comprising titrating the pH of the liquid enzyme formulation to a range of pH 6.0-8.0. | 2019-04-04 |
20190100739 | METHODS FOR THE MANUFACTURE OF PROTEOLYTICALLY PROCESSED POLYPEPTIDES - The present invention relates to a novel protcolytically active polypeptide and various uses of the polypeptide (and others) in screening and manufacturing methods. | 2019-04-04 |
20190100740 | Modified Strains for the Production of Recombinant Silk - Disclosed herein are modified strains for reducing degradation of recombinantly expressed products secreted from a host organism and methods of using the modified strains. | 2019-04-04 |
20190100741 | BIOSYNTHESIS OF PRODUCTS FROM 1-CARBON COMPOUNDS - An engineered microbe that contains a designed platform for the conversion of one-carbon substrates to chemical products is described. The designed platform embodies a new metabolic architecture that consolidates carbon fixation, central metabolism, and product synthesis into a single pathway. This is made possible by the key finding that 2-hydroxyacyl-CoA lyase, an enzyme in the α-oxidation pathway, is capable of catalyzing the C—C bond formation between formyl-CoA and aldehydes of different chain lengths, allowing for the elongation of the carbon backbone of said aldehyde by one-carbon units. These novel microbes present an opportunity for the production of chemicals from single-carbon feedstocks such as carbon dioxide, carbon monoxide, formate, formaldehyde, methanol or methane. | 2019-04-04 |
20190100742 | 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS - Described are 3-methylcrotonic acid decarboxylase (MDC) variants showing an improved activity in converting 3-methylcrotonic acid into isobutene as well as methods for the production of isobutene using such enzyme variants. | 2019-04-04 |
20190100743 | METHOD OF MAKING A VACCINE - A method of producing attenuated cells for a mammalian vaccine comprising killing or attenuating the cells with a high energy, low heat UV light. | 2019-04-04 |
20190100744 | METHOD OF MAKING A VACCINE - A method of producing attenuated cells for a mammalian vaccine comprising killing or attenuating the cells with a high energy, low heat UV light. | 2019-04-04 |
20190100745 | NOVEL CAS SYSTEMS AND METHODS OF USE - Compositions and methods are provided for genome modification of a target sequence in the genome of a cell. The methods and compositions employ a guide polynucleotide/Cas endonuclease system to provide an effective system for modifying or altering target sequences within the genome of a cell or organism. Also provided are Cas endonucleases comprising previously undefined nuclease domains and methods employing said Cas endonucleases for production of a guide polynucleotide/Cas endonuclease systems, for genome editing of a nucleotide sequence in the genome of a prokaryotic or eukaryotic cell, and/or for inserting or deleting a polynucleotide of interest into or from the genome of an organism. | 2019-04-04 |
20190100746 | USE OF AN AQUEOUS COMPOSITION FOR DISSOLVING BIOMOLECULES FROM A TISSUE SAMPLE - The present invention relates to the use of an aqueous composition for dissolving biomolecules from a tissue sample and to a method of using an aqueous composition for dissolving biomolecules from a tissue sample. Furthermore, the present invention relates to a system for preparing a tissue sample of an animal. | 2019-04-04 |
20190100747 | PURIFICATION AND DETECTION OF ANALYTES - A sample preparation module accepts a sample including a target analyte. The sample preparation module processes the sample through several reaction chambers and a solid phase column. Different reagents are present in the reaction chambers. The eluted analyte is then transferred to the amplification module, where it is further processed and amplified for optical analysis. | 2019-04-04 |
20190100748 | REMOVAL OF DNA FRAGMENTS IN MRNA PRODUCTION PROCESS - The present invention describes methods of removing DNA from an RNA transcript during the mRNA production process. The method embodies procedures for obtaining an in vitro transcription product, and removing any DNA from the product. The DNA can be removed by adding either free DNase or a resin containing immobilized DNase to the product, and recovering the RNA transcript. Alternatively, the DNA template used in the in vitro transcription reaction is labeled. After transcription, the product is applied to a resin that is configured to bind the label, and the RNA transcript is recovered. To detect whether any residual impurities are left in the RNA transcript product, the product is subjected to nuclease digestion and subsequently to liquid chromatography-tandem mass spectrometry analysis to quantitate any residual DNA. The present invention demonstrates efficient and effective methods of isolating an RNA transcript from an in vitro transcription product. | 2019-04-04 |
20190100749 | A Method for Prenatal Diagnosis Using Digital PCR - The present invention relates to a method for prenatal diagnosis using digital PCR, and more particularly to a method for providing information for diagnosis of chromosomal aneuploidy in a fetus, comprising: (a) extracting DNAs from pregnant woman's blood; (b) classifying the DNAs according to size to obtain DNAs having a size of 1,000 bp or less; (c) performing digital PCR using the obtained DNAs of step (b), for a control gene located on a chromosome not associated with chromosomal aneuploidy and a target gene located on a chromosome associated with chromosomal aneuploidy; (d) calculating a ratio of a quantitative digital PCR value of the target gene to a quantitative digital PCR value of the control gene; and (e) determining that when the ratio calculated in step (d) is 0.70-1.14, a chromosome number of the fetus is normal. | 2019-04-04 |
20190100750 | Rapid Methods for the Extraction of Nucleic Acids from Biological Samples - The invention is directed to compositions and methods for rapidly and efficiently extracting nucleic acids and/or targeted nucleic acids sequences from biological samples. The methods of the invention comprise combining the sample with a buffer and magnetic silicon beads and concentrating the beads with a magnet or other electrical field. Liquid may be removed, or not, and an alkaline buffer is added followed by magnetic carboxy beads in a binding buffer so that nucleic acids transfer to the carboxy beads, which can be easily and quickly isolated once again with a magnet. Total nucleic acid extraction is greatly enhanced. Extracted nucleic acids can be analyzed, for example, by PCR wherein the nucleic acids can be identified and characterized. Carboxy beads may also contain a ligand so as to target specific nucleic acid sequences. The invention is also directed to kits comprising the tools and compositions for performing the methods of the invention. | 2019-04-04 |
20190100751 | METHODS FOR SORTING NUCLEIC ACIDS AND MULTIPLEXED PREPARATIVE IN VITRO CLONING - Methods and compositions relate to the sorting and cloning of high fidelity nucleic acids using high throughput sequencing. Specifically, nucleic acid molecules having the desired predetermined sequence can be sorted from a pool comprising a plurality of nucleic acids having correct and incorrect sequences. | 2019-04-04 |
20190100752 | CHEMICALLY MODIFIED MESSENGER RNA'S - This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules. | 2019-04-04 |
20190100753 | Nuclease Resistant Polynucleotides and Uses Thereof - The invention provides, among other things, methods of stabilizing mRNA and nuclease resistant mRNA prepared in accordance with such methods. In certain embodiments, the nuclease resistant mRNA encodes a functional protein, such as enzyme, and is characterized by its resistance to nuclease digestion, increased half-life and/or its ability to produce increased amounts of the functional protein (e.g., enzyme) encoded thereby. | 2019-04-04 |
20190100754 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53 - The invention relates a method wherein a molecule is used for inducing and/or promoting skipping of at least one of exon 43, exon 46, exons 50-53 of the DMD pre-mRNA in a patient, preferably in an isolated cell of a patient, the method comprising providing said cell and/or said patient with a molecule. The invention also relates to said molecule as such. | 2019-04-04 |
20190100755 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES - The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims. | 2019-04-04 |
20190100756 | CpG-OLIGODEOXYNUCLEOTIDE, IMMUNOGENIC COMPOSITION INCLUDING THE SAME, AND METHOD OF INDUCING IMMUNE RESPONSE BY THE SAME - A CpG-oligodeoxynucleotide (CpG-ODN) for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof in a host is provided. The CpG-ODN includes one or more copies of the sequences of GTCGTT, one or more copies of the sequences of GTT and one or more copies of the sequences of TTTT, wherein at least one copy of the sequence of GTCGTT is encoded between the sequence of GTT and the sequence of TTTT. Further, an immunogenic composition including the CpG-ODN and a method of inducing immune response by the same are also provided. | 2019-04-04 |
20190100757 | CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING - Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans. | 2019-04-04 |
20190100758 | Methods of Treating Colorectal Cancer - Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer. | 2019-04-04 |
20190100759 | COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES - The present disclosure provides expression vectors comprising at least two nucleic acid sequences, namely a nucleic acid sequence encoding an anti-HPRT RNAi, and a nucleic acid sequence encoding a gamma globin gene. In some embodiments, the viral vector is a self-inactivating lentiviral vector. In some embodiments, the gamma-globin gene is used to genetically correct sickle cell disease or β-thalassemia or to reduce symptoms thereof. | 2019-04-04 |
20190100760 | METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS - In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGFβ signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell. | 2019-04-04 |
20190100761 | COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION AND VIRAL REPLICATION - The invention generally relates to compositions (including polynucleotides, constructs, fusion proteins, vectors, and cells) and methods of using such compositions for enhancing gene expression, protein production and viral replication. More specifically, the invention relates to use of m | 2019-04-04 |
20190100762 | NOVEL CAS9 SYSTEMS AND METHODS OF USE - Compositions and methods are provided for novel Cas9 systems, including, but not limiting to, novel guide polynucleotide/Cas9 endonucleases complexes, single or dual guide RNAs, guide RNA elements, and Cas9 endonucleases. The present disclosure also describes methods for genome modification of a target sequence in the genome of a cell, for gene editing, and for inserting a polynucleotide of interest into the genome of a cell. Also provided are nucleic acid constructs and cells having an altered target site or altered polynucleotide of interest produced by the methods described herein. | 2019-04-04 |
20190100763 | Haploid Induction Compositions and Methods for Use Therefor - Provided are isolated cDNAs comprising a nucleotide sequence having at least 90% identity to SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 52 or SEQ ID NO: 53. Also provided are expression cassettes; vectors; transgenic plant cells; plants, plant parts, and seeds; isolated polypeptides; amplicons and informative fragments of the presently disclosed nucleic acids; compositions that include amplification primer pairs; methods for producing plants that exhibit HI; methods for identifying the presence or absence of an allele associated with HI in a plant; methods for introgressing Haploid—inducing nucleotide sequences into plants; and methods for selecting parental plants predicted to produce progeny generations with plants that exhibit Haploid Induction trait. | 2019-04-04 |
20190100764 | PLANT PROMOTER FOR TRANSGENE EXPRESSION - This disclosure concerns compositions and methods for promoting transcription of a nucleotide sequence in a plant or plant cell, employing a promoter from a | 2019-04-04 |
20190100765 | AP2 DOMAIN TRANSCRIPTION FACTOR ODP2 (OVULE DEVELOPMENT PROTEIN 2) AND METHODS OF USE - Methods and compositions for modulating plant development are provided. Nucleotide sequences and amino acid sequences encoding Ovule Development Protein 2 (ODP2) proteins are provided. The sequences can be used in a variety of methods including modulating development, developmental pathways, altering oil content in a plant, increasing transformation efficiencies, modulating stress tolerance, and modulating the regenerative capacity of a plant. Transformed plants, plant cells, tissues, and seed are also provided. | 2019-04-04 |
20190100766 | METHOD FOR INCREASING NITROGEN-USE EFFICIENCY IN PLANTS - Disclosed herein is a method of improving yield, growth and/or nitrogen use efficiency in plants comprising altering the expression profile of NRT. Also provided methods of making such plants, including nucleic acid constructs and genetically altered plants with the above traits. | 2019-04-04 |
20190100767 | POLYNUCLEOTIDES, POLYPEPTIDES ENCODED THEREBY, AND METHODS OF USING SAME FOR INCREASING ABIOTIC STRESS TOLERANCE AND/OR BIOMASS AND/OR YIELD IN PLANTS EXPRESSING SAME - Provided are methods of increasing tolerance of a plant to abiotic stress, and/or increasing biomass, growth rate, vigor and/or yield of a plant. The methods are effected by expressing within the plant an exogenous polynucleotide encoding a polypeptide comprising an amino acid sequence at least 90% homologous to the amino acid sequence selected from the group consisting of SEQ ID NOs:201, 207, 212, 202-206, 208-211, 213-391, 1655, 961-1529, and 1660-1663. Also provided are polynucleotides, nucleic acid constructs, polypeptides and transgenic plants expressing same which can be used to increase tolerance of a plant to abiotic stress, and/or increase biomass, growth rate, vigor and/or yield of a plant. | 2019-04-04 |
20190100768 | Tospovirus Resistant Plants and Methods Thereof - The present invention provides tomato plants exhibiting resistance to TOSPO (GBNV) Virus exhibiting the traits of healthy and evenly ripened fruits without brown spots, reduced wilting of the top portion of the tomato plants and reduced dark spots on the leaves and stems of the tomato plant, and materials useful for improving tomato yield. In particular, the present invention provides a path to development of hybrid tomato plants exhibiting resistance to TOSPO virus infection, seed of hybrid tomato plants exhibiting TOSPO virus resistance, and methods of producing the same. Methods described herein involve the use of marker assisted selection and marker assisted backcrossing utilizing molecular markers associated with a tomato TOSPO Resistance phenotype. | 2019-04-04 |
20190100769 | MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR - Described herein are methods and compositions that enable rapid generation of high-order combinations of genetic elements comprising a CRISPR guide sequence and a scaffold sequence, and a barcode for rapid identification of the combination of genetic elements encoded within a single cell or a pooled population. Also described herein compositions of inhibitors of epigenetic genes and methods for reducing cell proliferation and/or treating cancer. | 2019-04-04 |
20190100770 | DESIGN METHOD FOR SYNTHETIC GENES - The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes. | 2019-04-04 |
20190100771 | Transgenic rabbit with common light chain - Herein is reported a transgenic vector comprising a humanized light chain locus, wherein said humanized light chain locus comprises (a) a V gene segment derived from human light chain V segment IGKV1-39-01, (b) 3′ proximal to said light chain gene segment a promoter, and (c) 5′ proximal to said light chain gene segment at least a fragment of the human IGKJ4 J-element. | 2019-04-04 |
20190100772 | NON-HUMAN ANIMALS EXPRESSING HUMANIZED C1Q COMPLEX - Disclosed herein are nucleic acids encoding for and proteins expressing chimeric C1q polypeptides, non-human animals comprising said nucleic acids, and methods of making or using said non-human animals. | 2019-04-04 |
20190100773 | METABOLICALLY ACTIVATED RECOMBINANT VIRAL VECTORS AND METHODS FOR THEIR PREPARATION AND USE - Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence. | 2019-04-04 |
20190100774 | MODIFICATION OF CELLS BY INTRODUCTION OF EXOGENOUS MATERIAL - The present disclosure provides methods and devices for rapid and efficient modification of a variety of cell types, including mammalian cells, plant cells, archaea, yeasts, and bacteria, by novel methods of introducing exogenous materials, e.g. nucleic acids. | 2019-04-04 |
20190100775 | ENGINEERED NUCLEIC ACID-TARGETING NUCLEIC ACIDS - The present disclosure provides engineered polynucleotide sequences that form scaffolds and nucleoprotein complexes comprising such engineered polynucleotide sequences that form scaffolds and nucleic acid binding proteins. Nucleic acid sequences encoding the engineered polynucleotide sequences that form scaffolds, as well as expression cassettes, vectors and cells comprising such polynucleotide sequences, are described. A variety of methods for making and using the engineered polynucleotide sequences that form scaffolds are also disclosed. | 2019-04-04 |
20190100776 | GLUCOSE COMPOSITION, MICROBIAL FERMENTATION RAW MATERIAL, AND METHOD OF PRODUCING CHEMICAL PRODUCT - A glucose composition contains, as equivalents in an aqueous solution of the composition having a glucose concentration of 100 g/L, 0-25 g/L of xylose, 0.1-10 g/L of acetic acid, 0.15-2.0 g/L of coumaric acid, and 0.007-0.28 g/L of ferulic acid. By using this glucose composition as a raw material in a method for producing a chemical product by microbial fermentation, the yield of the chemical product can be raised. | 2019-04-04 |
20190100777 | Host Cells and Methods for Production of Isobutanol - The invention relates to recombinant host cells having at least one integrated polynucleotide encoding a polypeptide that catalyzes a step in a pyruvate-utilizing biosynthetic pathway, e.g., pyruvate to acetolactate conversion. The invention also relates to methods of increasing the biosynthetic production of isobutanol, 2,3-butanediol, 2-butanol or 2-butanone using such host cells. | 2019-04-04 |
20190100778 | ENZYMES AND METHODS FOR DEALKYLATION OF SUBSTRATES - Disclosed herein are enzymes and organisms useful for the dealkylation of products derived from lignin depolymerization, including the conversion of guaiacol or guaethol to catechol or the conversion of anisole to phenol. Methods of converting guaiacol or guaethol to catechol or anisole to phenol using enzymes or organisms expressing the same are also disclosed. | 2019-04-04 |
20190100779 | PROCESS FOR PRODUCING LACTIC ACID OR ITS SALTS FROM FERMENTATION USING THERMOTOLERANCE BACILLUS BACTERIA - This invention relates to a process for producing lactic acid or its salts that can be performed easily, reduce complicated steps, and provide high lactic acid yield and high productivity, wherein said process comprising the following steps: (a) cultivating thermotolerance | 2019-04-04 |
20190100780 | TAILORED OILS PRODUCED FROM RECOMBINANT OLEAGINOUS MICROORGANISMS - Methods and compositions for the production of oil, fuels, oleochemicals, and other compounds in recombinant microorganisms are provided, including oil-bearing microorganisms and methods of low cost cultivation of such microorganisms. Microalgal cells containing exogenous genes encoding, for example, a lipase, a sucrose transporter, a sucrose invertase, a fructokinase, a polysaccharide-degrading enzyme, a keto acyl-ACP synthase enzyme, a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty acid hydroxylase, a desaturase enzyme, a fatty aldehyde decarbonylase, and/or an acyl carrier protein are useful in manufacturing transportation fuels such as renewable diesel, biodiesel, and renewable jet fuel, as well as oleochemicals such as functional fluids, surfactants, soaps and lubricants. | 2019-04-04 |
20190100781 | COMPOSITIONS AND METHODS FOR PRODUCING BENZYLISOQUINOLINE ALKALOIDS - The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound. The invention also relates to methods of producing the benzylisoquinoline, as well as select precursors and intermediates thereof by culturing the host cells under culture conditions that promote expression of the enzymes that produce the benzylisoquinoline or precursors or intermediates thereof. | 2019-04-04 |
20190100782 | ENZYMATICALLY PRODUCED CELLULOSE - Enzymatic reactions are disclosed herein comprising water, glucose-1-phosphate, cellodextrin, and at least one cellodextrin phosphorylase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:2 or SEQ ID NO:6. These reactions produce a low molecular weight, insoluble cellulose with enhanced features. | 2019-04-04 |
20190100783 | MODIFIED TYPE A DNA POLYMERASES - The present invention provides improved DNA polymerases, in particular, type A DNA polymerases, that may be better suited for applications in recombinant DNA technologies. Among other things, the present invention provides modified DNA polymerases derived from directed evolution experiments designed to select mutations that confer advantageous phenotypes under conditions used in industrial or research applications. | 2019-04-04 |
20190100784 | RNA ANALYSIS BY TOTAL HYDROLYSIS - The present invention relates to analysis of an RNA molecule. It further relates to the use of this method for the quality control of an RNA molecule produced by in vitro transcription or for the quality control of an RNA molecule produced by chemical synthesis. | 2019-04-04 |
20190100785 | METHOD OF PRODUCING UNDENATURED COLLAGEN FROM CARTILAGE WITH LOW TEMPERATURE HYDROLYSIS - A method of producing undenatured collagen from cartilage uses a low temperature hydrolysis. To begin, cartilage, citric/lactic acid, and water are added to a digestion vessel and stirred. Next, a base and acid stable protease are added and the mixture is stirred again before being set aside. Bones and fat are removed leaving a liquid mixture to which a base is added. Sediment is then filtered, removed, and dried from the liquid mixture to form a collagen powder. | 2019-04-04 |
20190100786 | MULTI-WELL-BASED CELL CULTURE TEST DEVICE FOR RAPID ANTIBIOTIC SUSCEPTIBILITY TESTING - Provided is a multi-well-based cell culture test device having an array structure of a plurality of aligned well units. Each of the well units includes a first sub-well adapted to accommodate a first fluid, a second sub-well adapted to accommodate a second fluid, and a barrier located between the first sub-well and the second sub-well to partition the first sub-well and the second sub-well. The first sub-well has a recess in the depth direction with respect to its bottom to accommodate a solid thin film formed by solidifying the first fluid. The barrier has such a height that the first fluid does not overflow into the second sub-well when the first fluid is loaded into the first sub-well to fill the recess | 2019-04-04 |
20190100787 | COMPOSITIONS AND METHODS FOR DETECTION OF TRICHOMONAS VAGINALIS - Methods for the rapid detection of the presence or absence of | 2019-04-04 |
20190100788 | ISOLATION OF NUCLEIC ACIDS - Provided herein is technology relating to isolating nucleic acids. In particular, the technology relates to methods and kits for extracting nucleic acids from problematic samples such as stool. | 2019-04-04 |
20190100789 | METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS INFECTIOUS DISEASE AND OTHER HEALTH CONDITIONS ASSOCIATED WITH ANTIBIOTIC USAGE - Methods, compositions, and systems are provided for detecting one or more effects of antibiotic usage for an infectious disease or other health condition on the microbiome of an individual, monitoring such effects, and/or determining, displaying, or promoting a therapy for such an effect. Methods, compositions, and systems are also provided for generating and comparing microbiome composition and/or functional diversity datasets. Methods, compositions, and systems are also provided for generating a characterization model for antibiotic usage. | 2019-04-04 |
20190100790 | DETERMINATION OF NOTCH PATHWAY ACTIVITY USING UNIQUE COMBINATION OF TARGET GENES - A bioinformatics process which provides an improved means to detect a Notch cellular signaling pathway in a subject, such as a human, based on the expression levels of at least three unique target genes of the Notch cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of Notch cellular signaling pathway target genes. | 2019-04-04 |
20190100791 | SENSOR APPARATUS AND METHOD FOR TESTING A SAMPLE - A sensor apparatus for testing a biological sample, a system making use thereof and a method for testing a biological sample with the sensor apparatus and system. | 2019-04-04 |
20190100792 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME - Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes described specifically label only their target active enzymes involved in xenobiotic metabolism and therefore provide a measurement of true protein functional activity rather than transcript or protein abundance. The activity-based probes also provide multimodal profiling of these active enzymes. Methods for preparing the activity based probes and exemplary methods for their use also are disclosed. | 2019-04-04 |
20190100793 | METHODS AND SYSTEMS FOR RNA OR DNA DETECTION AND SEQUENCING - Disclosed are methods and systems for detecting RNA and sequencing RNA in a wide range of samples such as samples with low concentrations of nucleic acid, samples with degraded nucleic acid, samples that would not otherwise be amenable to conventional sequencing or RNA detection methods, poor quality samples, high quality samples in which rare mutations are sought, formalin-fixed paraffin-embedded samples, blood samples, etc. The methods of the present invention may use paired, large panels of primers to amplify many short fragments that overlap between but not within each panel. Each panel's amplicon set may fill the gaps between those of the opposing panel, thereby providing complete gene or genomic coverage. A preliminary, multiplex amplification step amplifies target nucleic acid for all downstream reactions such as Sanger sequencing, cloning, and Next Generation Sequencing (NGS). | 2019-04-04 |
20190100794 | Blood matrix metalloproteinase 9 (MMP9) is a predictive biomarker for cardiac diseases and disorders - The present invention relates to compositions and methods useful for the assessment, diagnosis, and treatment of myocardial infarctions. | 2019-04-04 |
20190100795 | DETERMINATION OF JAK-STAT1/2 PATHWAY ACTIVITY USING UNIQUE COMBINATION OF TARGET GENES - A bioinformatics process which provides an improved means to detect a JAK-STAT1/2 cellular signaling pathway in a subject, such as a human, based on the expression levels of at least three unique target genes of the JAK-STAT1/2 cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of JAK-STAT1/2 cellular signaling pathway target genes. | 2019-04-04 |
20190100796 | Compositions and Methods for Analyzing Modified Nucleotides - A method for identifying any of the presence, location and phasing of modified cytosines (C) in long stretches of nucleic acids is provided. In some embodiments, the method may comprise (a) reacting a first portion of a nucleic acid sample containing at least one C and/or at least one modified C with a DNA glucosyltransferase and a cytidine deaminase to produce a first product and/or reacting a second portion of the sample with a dioxygenase, optionally a DNA glucosyltransferase and a cytidine deaminase to produce a second product and; (b) comparing the sequences from the first and optionally the second product obtained in (a), or amplification products thereof, with each other and/or an untreated reference sequence to determine which Cs in the initial nucleic acid fragment are modified. A modified TET methylcytosine dioxygenase with improved efficiency compared to unmodified TET2 at converting methylcytosine to carboxymethylcytosine is also provided. | 2019-04-04 |
20190100797 | SYSTEMS AND METHODS FOR PAIRED END SEQUENCING - Systems and methods for analyzing overlapping sequence information can obtain first and second overlapping sequence information for a polynucleotide, align the first and second sequence information, determine a degree of agreement between the first and second sequence information for a location along the polynucleotide, and determine a base call and a quality value for the location. | 2019-04-04 |
20190100798 | DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELS - Compositions, methods and kits are disclosed for high-sensitivity single molecule digital counting by the stochastic labeling of a collection of identical molecules by attachment of a diverse set of labels. Each copy of a molecule randomly chooses from a non-depleting reservoir of diverse labels. Detection may be by a variety of methods including hybridization based or sequencing. Molecules that would otherwise be identical in information content can be labeled to create a separately detectable product that is unique or approximately unique in a collection. This stochastic transformation relaxes the problem of counting molecules from one of locating and identifying identical molecules to a series of binary digital questions detecting whether preprogrammed labels are present. The methods may be used, for example, to estimate the number of separate molecules of a given type or types within a sample. | 2019-04-04 |
20190100799 | COMPOSITIONS AND METHODS OF DETECTING MYELITIS - The present invention relates to novel compositions and methods for detecting myelitis. The invention also relates to methods of identifying mutations in VPS37a indicative of monophasic acute transverse myelitis. | 2019-04-04 |
20190100800 | Epigenetic Method for the Identification of Follicular T-Helper-(TFH-) Cells - The present invention relates to a method, in particular an in vitro method, for identifying follicular helper T cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for leukemia inhibitory factor (LIF), wherein a demethylation of said gene region is indicative for a follicular helper T cell, when compared to a non-follicular helper T cell. The analyses according to the invention can identify follicular helper T cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood cells. The present invention furthermore provides an improved method for quantifying follicular helper T cells in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. | 2019-04-04 |
20190100801 | COMPOSITIONS AND METHODS FOR EVALUATING AND MODULATING IMMUNE RESPONSES BY USE OF IMMUNE CELL GENE SIGNATURES - The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response. | 2019-04-04 |
20190100802 | MARKER FOR PREDICTING PRESSURE ULCER DEVELOPMENT AND USE THEREOF - A marker for predicting pressure ulcer development, selected from the group consisting of interleukin (IL)-1α, vascular endothelial growth factor (VEGF)-C, plasminogen activator inhibitor (PAI)-1, and heat-shock protein (HSP) 90α. | 2019-04-04 |
20190100803 | COMPOSITIONS FOR CHARACTERIZING DEVELOPMENT OF ESOPHAGEAL ADENOCARCINOMA IN PATIENTS AND METHODS OF USE THEREOF - The present invention is a method, comprising: obtaining a sample of an esophageal tissue from a subject, wherein the sample of the esophageal tissue comprises or is suspected of comprising a break of chromosome 2 (chr2), a break of chromosome 10 (chr10), a break of chromosome 16 (chr16), or any combination thereof, and detecting in the sample of esophageal tissue whether the break of chr2 is present, whether the break of chr10 is present, whether the break of chr16 is present, or any combination thereof, by contacting the sample of esophageal tissue with a first detectably labeled probe, a second detectably labeled probe, a third detectably labeled probe, or any combination thereof, and detecting binding between: the first detectably labeled probe and the break of chr2, the second detectably labeled probe and the break of chr10, the third detectably labeled probe and the break of chr16, or any combination thereof. | 2019-04-04 |
20190100804 | METHOD FOR DETECTING CYSTIC FIBROSIS - The present invention relates to methods for simultaneously determining the presence or absence of mutations, deletions, duplications and single nucleotide polymorphisms in a cystic fibrosis transmembrane regulator (CFTR) nucleic acid. Oligonucleotide primers and kits used to amplify regions of a CFTR nucleic acid for high throughput, massively parallel sequencing and methods of determining an individual's cystic fibrosis status are also disclosed. | 2019-04-04 |
20190100805 | THYROID CANCER DIAGNOSTICS - Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods for determining the treatment modality of a cancer in a subject. The methods comprise expression-based analysis of targets. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. | 2019-04-04 |
20190100806 | MARKER FOR PREDICTING TREATMENT RESPONSE TO ANTI-CANCER AGENT IN SOLID CANCER PATIENTS - The present invention relates to a marker for predicting a responsiveness of a solid cancer patient to an anticancer agent. The marker according to the present invention can be advantageously used to select a subgroup, who effectively responds to an anticancer therapy with a specific anticancer agent, from among solid cancer patients, or to determine a therapy method for treatment of solid cancer patients. | 2019-04-04 |
20190100807 | COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID - The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease. | 2019-04-04 |
20190100808 | NUCLEIC ACID DETECTION COMBINING AMPLIFICATION WITH FRAGMENTATION - Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes. | 2019-04-04 |
20190100809 | ALGORITHMS FOR DISEASE DIAGNOSTICS - The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis. | 2019-04-04 |
20190100810 | MONITORING HEALTH AND DISEASE STATUS USING CLONOTYPE PROFILES - There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers. | 2019-04-04 |
20190100811 | PHAGE-BASED DETECTION METHOD FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING AND IDENTIFICATION OF BACTERIAL SPECIES - Methods for determining bacterial identity and susceptibility or resistance to antibiotic or antimicrobial agents are provided. In one embodiment, the bacteria is cultured in the presence or absence or the antibiotic agent to generate a plurality of primary cultures, which are then cultured in the presence or absence of transforming phages to generate a first secondary culture that comprise transformed bacteria that have been treated with the antibiotic agent and a second secondary culture that comprises transformed bacteria that have not been treated with the antibiotic agent. The recombinant phages are specific to the bacteria and comprise a heterologous marker. The susceptibility or resistance of the bacteria to the antibiotic or antimicrobial agent is determined by comparing a level or activity of the marker in the first and second secondary cultures. | 2019-04-04 |
20190100812 | ASSAY FOR DETECTING HUMAN IMMUNODEFICIENCY VIRUS (HIV) - The disclosure is directed to methods, kits, and compositions for amplifying and detecting a human immunodeficiency virus-1 (HIV-1) in a sample, which comprises a variety of combinations of forward oligonucleotide primers, reverse oligonucleotide primers, and oligonucleotide probes. | 2019-04-04 |
20190100813 | ASSAY FOR DETECTING HEPATITIS C VIRUS (HCV) - The disclosure is directed to methods, kits, and compositions, for amplifying and detecting a human hepatitis C virus (HCV) in a sample, which comprises a variety of combinations of forward oligonucleotide primers, reverse oligonucleotide primers, and oligonucleotide probes. | 2019-04-04 |
20190100814 | Hyper-Producing Trichoderma Reesei Strain Having an Enhanced Beta-Glucosidase Activity - The present invention relates to a | 2019-04-04 |
20190100815 | WATER-SOLUBLE QUENCHING OIL COMPOSITION - A water-soluble quenching fluid composition prepared by blending: water, at least one kind selected from a polyoxyalkylene glycol and a derivative thereof (A), and at least one kind selected from an alkylene glycol ether (B) and a monocarboxylic acid (C), the polyoxyalkylene glycol or a derivative thereof (A) having a mass average molecular weight of 10,000 or more and 100,000 or less, the alkylene glycol ether (B) having a boiling point of 200° C. or more and a molecular weight per 1 mol of 1,000 g/mol or less. | 2019-04-04 |
20190100816 | MOLD, MOLD APPARATUS, AND COOLING METHOD FOR WORKPIECE - In a mold, at least one of a lower mold and an upper mold includes a coolant supply passage through which a liquid coolant is supplied to an inner space of a recess, and the mold includes an air escape passage through which air in the inner space of the recess is discharged upward. | 2019-04-04 |
20190100817 | DEHYDROGENATION PROCESSING METHOD FOR TURBINE BLADES - A dehydrogenation processing method for a turbine blade of a steam turbine includes: a step of heating the turbine blade by supplying heating steam into a casing of the steam turbine when a steam turbine plant is started or stopped. | 2019-04-04 |
20190100818 | HIGH-STRENGTH STEEL PLATE FOR PRESSURE VESSEL HAVING EXCELLENT TOUGHNESS AFTER POST WELD HEAT TREATMENT AND MANUFACTURING METHOD THEREOF - Provided is a high-strength steel plate for a pressure vessel having excellent low temperature toughness after a post weld heat treatment (PWHT). The high-strength steel plate for a pressure vessel includes: by wt %, 0.02-0.15% of carbon (C), 0.05-0.50% of silicon (Si), 1.0-2.0% of manganese (Mn), 0.005-0.1% of aluminum (Al), 0.015% or less of phosphorus (P), 0.0015% or less of sulfur (S), 0.01-0.03% of niobium (Nb), 0.01-0.03% of vanadium (V), 0.01-0.03% of titanium (Ti), 0.005% or less of chromium (Cr), 0.005% or less of molybdenum (Mo), 0.02-0.50% of copper (Cu), 0.05-0.60% of nickel (Ni), 0.0002-0.0010% of boron (B), 0.0035-0.0065% of nitrogen (N), and a balance of iron (Fe) and other inevitable impurities. A microstructure of the high-strength steel plate includes a complex structure of ferrite having an area fraction of 35-40% and a balance of bainite, and the bainite has a packet size of 15 μm or less. | 2019-04-04 |
20190100819 | STEEL SHEET, COATED STEEL SHEET, METHOD FOR PRODUCING HOT-ROLLED STEEL SHEET, METHOD FOR PRODUCING COLD-ROLLED FULL HARD STEEL SHEET, METHOD FOR PRODUCING HEAT-TREATED SHEET, METHOD FOR PRODUCING STEEL SHEET, AND METHOD FOR PRODUCING COATED STEEL SHEET - A steel sheet is provided that has a tensile strength of 540 MPa or more, includes a particular composition; and has a steel structure containing ferrite and a secondary phase, in which an area fraction of the ferrite is 50% or more, the secondary phase contains 1.0% or more and 25.0% or less of martensite in terms of area fraction with respect to the entirety, the ferrite has an average crystal grain size of 3 μm or more, a difference in hardness between the ferrite and the martensite is 1.0 GPa or more and 8.0 GPa or less, and, in a texture of the ferrite, an inverse intensity ratio of γ-fiber to α-fiber is 0.8 or more and 7.0 or less. | 2019-04-04 |
20190100820 | 3-D PRINTED COOLING CHANNELS TO PRODUCE PHS PARTS WITH TAILORED PROPERTIES - A hot stamping die includes a body having a stamping surface, and cooling channels within the body. The cooling channels are positioned to transfer heat from region(s) of the surface to the channels. The hot stamping die also includes a heating element within the body, separate and apart from the channels. The heating element is positioned to heat region(s) of the body different from the region(s) of the surface at a rate greater than heat transfer from the channels to the region(s) of the surface. | 2019-04-04 |
20190100821 | HIGH-STRENGTH SEAMLESS STAINLESS STEEL PIPE AND METHOD OF MANUFACTURING HIGH-STRENGTH SEAMLESS STAINLESS STEEL PIPE - A high-strength seamless stainless steel pipe has a composition including, by mass %, 0.05% or less C, 1.0% or less Si, 0.1 to 0.5% Mn, 0.05% or less P, 0.005% or less S, more than 16.0% to 18.0% or less Cr, more than 2.0% to 3.0% or less Mo, 0.5 to 3.5% Cu, 3.0% or more and less than 5.0% Ni, 0.01 to 3.0% W, 0.01 to 0.5% Nb, 0.001 to 0.3% Ti, 0.001 to 0.1% Al, less than 0.07% N, 0.01% or less O, and Fe and unavoidable impurities as a balance, wherein the steel pipe has a microstructure including a tempered martensite phase forming a main phase, 20 to 40% of a ferrite phase in terms of volume ratio, and 25% or less of a residual austenite phase in terms of volume ratio, an average grain size of the ferrite phase is 40 μm or less, and a sum of amounts of Ti and Nb precipitated as precipitates having a grain size of 2 μm or less is 0.06 mass % or more, whereby the steel pipe has high strength where yield strength YS is 758 MPa or more and high toughness where an absorbing energy value vE | 2019-04-04 |
20190100822 | METHOD FOR JOINING STEEL RAILS WITH CONTROLLED WELD HEAT INPUT - A method for creating a welded joint between ends of two steel rails, wherein the two steel rails have a substantially pearlitic microstructure. The method includes a first heating step, an upsetting step, a first cooling step, and a second heating step and provides a means to influence a microstructure and hardness of an austenitic region of a heat affected zone (HAZ) and/or an extent of softening in a softened region of a HAZ. | 2019-04-04 |
20190100823 | SYSTEM AND METHOD FOR ABOVE-ATMOSPHERIC LEACHING OF METAL SULFIDES - A system and method for improving leach kinetics and recovery during above-atmospheric leaching of a metal sulfide is disclosed. In some embodiments, the method may comprise the steps of: (a) producing a metal sulfide concentrate [ | 2019-04-04 |
20190100824 | ALUMINUM ALLOY POWDER AND PRODUCTION METHOD THEREOF, AND ALUMINUM ALLOY EXTRUDED MATERIAL AND PRODUCTION METHOD THEREOF - An aluminum alloy powder consists of Fe: 5.0 mass % to 9.0 mass %, V: 0.1 mass % to 3.0 mass %, Mo: 0.1 mass % to 3.0 mass %, Zr: 0.1 mass % to 2.0 mass %, Ti: 0.02 mass % to 2.0 mass %, and the balance being Al and inevitable impurities. The aluminum alloy powder contains an Al—Fe based intermetallic compound. An average circle equivalent diameter of the Al—Fe based intermetallic compound is in a range of 0.1 μm to 3.0 μm in a cross-sectional structure of the aluminum alloy powder. An aluminum alloy extruded material excellent in mechanical properties at high temperature is provided. | 2019-04-04 |
20190100825 | CHROMIUM-BASED TWO-PHASE ALLOY AND PRODUCT USING SAID TWO-PHASE ALLOY - There is provided a Cr-based two-phase alloy including two phases of a ferrite phase and an austenite phase that are mixed with each other. A chemical composition of the Cr-based two-phase alloy consists of a main component, an auxiliary component, impurities, a first optional auxiliary component, and a second optional auxiliary component. The main component consists of 33-61 mass % Cr, 18-40 mass % Ni and 10-33 mass % Fe, and a total content of the Ni and the Fe is 37-65 mass %. The auxiliary component consists of 0.1-2 mass % Mn, 0.1-1 mass % Si, 0.005-0.05 mass % Al, and 0.02-0.3 mass % Sn. The impurities include 0.04 mass % or less of P, 0.01 mass % or less of S, 0.03 mass % or less of C, 0.04 mass % or less of N, and 0.05 mass % or less of O. | 2019-04-04 |
20190100826 | Ni-Fe-Cr Alloy - An objective of the present invention is to provide a Ni—Fe—Cr alloy having an excellent intergranular corrosion resistance. A Ni—Fe—Cr alloy of the present embodiment has a chemical composition consisting of, in mass percent, C: 0.005 to 0.015%, Si: 0.05 to 0.50%, Mn: 0.05 to 1.5%, P: 0.030% or less, S: 0.020% or less, Cu: 1.0 to 5.0%, Ni: 30.0 to 45.0%, Cr: 18.0 to 30.0%, Mo: 2.0 to 4.5%, Ti: 0.5 to 2.0%, N: 0.001 to 0.015%, and Al: 0 to 0.50%, with the balance being Fe and impurities. An average grain size d (μm) satisfies Formula (1): | 2019-04-04 |
20190100827 | NITRIDING OF NIOBIUM STEEL AND PRODUCT MADE THEREBY - A nitrided steel product or thin cast steel strip comprising, by weight, less than 0.25% carbon, between 0.20 and 2.0% manganese, between 0.05 and 0.50% silicon, less than 0.01% aluminum, niobium between 0.01 and about 0.20%, and between 0.01 and 0.075% nitrogen, and having a majority of the microstructure comprised of bainite and acicular ferrite, having more than 70% niobium in solid solution prior to nitriding and having yield strength between 650 MPa and 800 MPa and tensile strength between 750 MPa and 900 MPa. | 2019-04-04 |
20190100828 | FE-BASED NANOCRYSTALLINE ALLOY AND ELECTRONIC COMPONENT USING THE SAME - An Fe-based nanocrystalline alloy is represented by Composition Formula, (Fe | 2019-04-04 |
20190100829 | RECONDITIONING A CORE FOR USE IN AN ENERGY RECOVERY DEVICE - A system and method of reconditioning a SMA or NTE material based core for use in an energy recovery device comprising the step of heating the core for a period of time above a certain temperature to configure the core with its original properties. The system and method can be implemented on site of an energy recovery device or remotely. | 2019-04-04 |